ci 966 has been researched along with muscimol in 1 studies
| Studies (ci 966) | Trials (ci 966) | Recent Studies (post-2010) (ci 966) | Studies (muscimol) | Trials (muscimol) | Recent Studies (post-2010) (muscimol) |
|---|---|---|---|---|---|
| 14 | 0 | 4 | 4,699 | 9 | 887 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebert, U; Krnjević, K | 1 |
1 other study(ies) available for ci 966 and muscimol
| Article | Year |
|---|---|
Systemic CI-966, a new gamma-aminobutyric acid uptake blocker, enhances gamma-aminobutyric acid action in CA1 pyramidal layer in situ.
Topics: Animals; gamma-Aminobutyric Acid; Hippocampus; Iontophoresis; Male; Muscimol; Nipecotic Acids; Pharmaceutical Vehicles; Pyramidal Tracts; Pyridines; Rats; Rats, Inbred Strains | 1990 |